STALICLA SA is a Swiss clinical-stage biopharmaceutical company developing precision-medicine approaches for neurodevelopmental and neuropsychiatric disorders. The company employs a multi-omics DEPI platform to identify patient subgroups and match them with targeted therapeutic candidates; its pipeline includes subgroup-matched programs such as STP1 for Autism Spectrum Disorder and STP7 for Substance Use Disorder, and it conducts clinical collaborations to advance these programs.
Leadership & Board
Current Number of Employees24
Current LinkedIn Followers5,656
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$3M
Total Amount Raised$3M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$3M
Latest Funding Amount$3M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
STALICLA had 24 employees as of April 6, 2026. The number of employees decreased by 1 (4.00%) week-over-week.
24Latest Employee Count
1(-4.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
STALICLA had 5,656 followers as of April 6, 2026. The number of followers increased by 2 (0.04%) week-over-week.
5,656Latest Followers Count
2(0.04%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.